Snider Financial Group Veracyte, Inc. Transaction History

Snider Financial Group

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 10, 2023	BUY	$20.58 - $27.89 $211,047 - $286,011	10,255 New	10,255 $228,000
Q3 2022 Nov 14, 2022	SELL	$16.58 - $27.9 $31,203 - $52,507	-1,882 Reduced 10.67%	15,754 $293,000
Q2 2022 Aug 15, 2022	BUY	$15.45 - $29.52 $67,408 - $128,795	4,363 Added 32.87%	17,636 $351,000
Q1 2022 May 13, 2022	BUY	$21.94 - $42.51 $82,669 - $160,177	3,768 Added 39.64%	13,273 $366,000
Q4 2021 Jan 18, 2022	BUY	$36.09 - $53.79 $14,905 - $22,215	413 Added 4.54%	9,505 $404,000
Q3 2021 Nov 05, 2021	SELL	$35.62 - $52.97 $2,386 - $3,548	-67 Reduced 0.73%	9,092 $435,000
Q2 2021 Aug 31, 2021	BUY	$32.94 - $56.62 $301,697 - $518,582	9,159 New	9,159 $349,000

311

82M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $3.14B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Snider Financial Group, based on Form 13F filings with the SEC.

Stay updated on Snider Financial Group with notifications on news.